What is Sinuwave?
Ondine Biomedical specializes in advanced therapies for chronic sinus conditions, most notably its Sinuwave treatment. This innovative therapy provides rapid, targeted antimicrobial and anti-inflammatory benefits for individuals suffering from chronic rhinosinusitis (CRS). Currently, Sinuwave is available exclusively in Canada, with plans to expand its reach. The company's mission is to deliver effective solutions that prevent complex infections and improve patient outcomes in the field of otolaryngology.
How much funding has Sinuwave raised?
Sinuwave has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Sinuwave
PPP
Public-Private Partnership
What's next for Sinuwave?
With substantial capital raised, Ondine Biomedical is poised for significant growth and market expansion. The recent strategic investment, alongside the existing debt financing, suggests a robust financial strategy aimed at scaling operations and potentially broadening the availability of the Sinuwave treatment beyond its current Canadian market. Future developments will likely focus on regulatory approvals in new territories, such as the United States, and further clinical validation of its antimicrobial and anti-inflammatory technologies. This late-stage funding context points towards a mature phase of development, with an emphasis on commercialization and market penetration.
See full Sinuwave company page
